Cancer Research Meeting Calendar  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelling, J.
Right arrow Articles by Jordan, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelling, J.
Right arrow Articles by Jordan, M. A.
[Cancer Research 63, 2794-2801, June 1, 2003]
© 2003 American Association for Cancer Research


Experimental Therapeutics

Suppression of Centromere Dynamics by Taxol® in Living Osteosarcoma Cells1

Jonathan Kelling, Kevin Sullivan, Leslie Wilson and Mary Ann Jordan2

Department of Molecular, Cellular, and Developmental Biology and the Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California 93106 [J. K., L. W., M. A. J.], and Department of Cell Biology, Scripps Research Institute, La Jolla, California 92037 [K. S.]

Taxol® potently blocks mitosis at the transition from metaphase to anaphase, leading to apoptosis in many types of tumor cells. However, the precise mechanism of action of Taxol® is not understood. Here we have tested the hypothesis that a primary mechanism of action of Taxol® involves suppression of spindle microtubule dynamics. We have used centromere-binding protein B coupled to green fluorescent protein as a marker for the kinetochores and centromeres of chromosomes and analyzed the effects of low Taxol® concentrations on the dynamics of centromeres during metaphase of mitosis in living human osteosarcoma (U2OS) cells by quantitative time-lapse confocal microscopy. In the absence of Taxol®, the centromere pairs on attached sister chromatids alternately stretch apart and relax back together approximately 1.2 times/min due to tension on the kinetochores produced by the spindle microtubules (referred to here as centromere dynamics). We found that 50–100 nM Taxol® significantly suppressed centromere dynamics. For example, Taxol® reduced the mean separation distance between the sister centromeres from 0.73 to 0.65 µm, a distance equivalent to that observed in the complete absence of microtubules. The frequency of transitions between stretching and relaxing was also significantly diminished by Taxol® (by 27%–35%). The suppressive effects of Taxol® on centromere dynamics were associated with maximal accumulation of cells at mitosis (63%), a >90% block of the metaphase/anaphase transition, and complete inhibition of cell proliferation. The data strongly support the idea that the inhibition of centromere dynamics by Taxol® prevents silencing of the mitotic spindle surveillance (checkpoint) mechanism. Because Taxol® strongly suppresses microtubule dynamics, the data also indicate that centromere dynamics can be accounted for by microtubule dynamics and may not require significant energetic contributions from microtubule motors. The strict correlation between the degree of suppression of centromere dynamics by Taxol® and the degree of mitotic block strongly indicates that the primary mechanism responsible for the mitotic block by Taxol® in U2OS cells involves suppression of the polymerization dynamics of kinetochore microtubules.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
K. E. Gascoigne and S. S. Taylor
How do anti-mitotic drugs kill cancer cells?
J. Cell Sci., August 1, 2009; 122(15): 2579 - 2585.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Yenjerla, C. Cox, L. Wilson, and M. A. Jordan
Carbendazim Inhibits Cancer Cell Proliferation by Suppressing Microtubule Dynamics
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 390 - 398.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
O. Azarenko, T. Okouneva, K. W. Singletary, M. A. Jordan, and L. Wilson
Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane
Carcinogenesis, December 1, 2008; 29(12): 2360 - 2368.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
Z. Yue, A. Carvalho, Z. Xu, X. Yuan, S. Cardinale, S. Ribeiro, F. Lai, H. Ogawa, E. Gudmundsdottir, R. Gassmann, et al.
Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell line
J. Cell Biol., October 20, 2008; 183(2): 279 - 296.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Okouneva, O. Azarenko, L. Wilson, B. A. Littlefield, and M. A. Jordan
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Mol. Cancer Ther., July 1, 2008; 7(7): 2003 - 2011.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S.-F. Lin, S. P. Gao, D. L. Price, S. Li, T.-C. Chou, P. Singh, Y.-Y. Huang, Y. Fong, and R. J. Wong
Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer
Clin. Cancer Res., March 1, 2008; 14(5): 1519 - 1528.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
F. Gasparri, P. Cappella, and A. Galvani
Multiparametric Cell Cycle Analysis by Automated Microscopy
J Biomol Screen, September 1, 2006; 11(6): 586 - 598.
[Abstract] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A.-J. Dijkhuis, K. Klappe, S. Jacobs, B.-J. Kroesen, W. Kamps, H. Sietsma, and J. W. Kok
PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy.
Mol. Cancer Ther., March 1, 2006; 5(3): 593 - 601.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, and L. Wilson
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
Mol. Cancer Ther., July 1, 2005; 4(7): 1086 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Z. Chen, P. J. Merta, N.-H. Lin, S. K. Tahir, P. Kovar, H. L. Sham, and H. Zhang
A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth
Mol. Cancer Ther., April 1, 2005; 4(4): 562 - 568.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. A. Lee, M. K. Keutmann, M. L. Dowling, E. Harris, G. Chan, and G. D. Kao
Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells
Mol. Cancer Ther., June 1, 2004; 3(6): 661 - 669.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Honore, K. Kamath, D. Braguer, L. Wilson, C. Briand, and M. A. Jordan
Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation
Mol. Cancer Ther., December 1, 2003; 2(12): 1303 - 1311.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.